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SUMMARY
Lung volumes and gas exchange were investigated prospectively in 96 patients with rheumatoid arthritis selected without regard
to pulmonary disorders and treated with i.m. methotrexate (MTX) injections [mean weekly dose 13.0 mg (5th-95th percentile
(5-95 PC) 7.6-20.8)]. Individual changes over time during MTX treatment [mean duration 2.9 yr (5-95 PC 0.4-5.3)] were assessed
by regression analyses in each individual. Forced vital capacity (FVQ remained stable in the majority of patients [mean annual
change +0.8% (5-95 PC —8.1 to +14.0) of calculated normal value]. In addition, transfer factor using the indicator gas CO
(Tuco) was unaltered in most patients [mean annual change - 2 . 1 % (5-95 PC -16.2 to +11.8) of predicted value]. However,
there were significant decreases in the forced expiratory volume in 1 s (FEV,) before and after inhalation of 0.2 mg salbutamol
[mean annual change - 0 . 8 % (5-95 PC -8 .4 to +3.2) and - 1 . 3 % (5-95 PC -7.8 to +3.9) of the FVC measured, respectively].
In addition, there were significant increases in alveolar-arterial Po, gradients (P(A-.W)J) at rest and after exercise [mean annual
change +1.7 mmHg (5-95 PC -5.2 to +12.2) and +1.8 mmHg (5-95 PC -3.5 to 9.0), respectively]. Nevertheless, the amounts
were small in view of the reliability of the methods applied and reflect, at least in part, the normal process of ageing. The annual
change in FEVi/FVC was negatively correlated with FEV,/FVC at baseline (R, = - 0.46, P < 0.001). The annual change in
TUco was also negatively correlated with Ti^o at baseline (Rs = —0.31, P = 0.028). No other risk factors for deterioration of
lung volumes or gas exchange were found, including mean weekly MTX dose, age, gender, smoking, presence of rheumatoid
factor and pulmonary function at baseline. We conclude that MTX has no major effect on pulmonary function in the majority
of patients and that there is no evidence that patients with pre-existing pulmonary disease are at increased risk for further
deterioration of lung function.
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LOW-DOSE weekly methotrexate (MTX) is increasingly
used in the treatment of rheumatoid arthritis (RA)
[1-3]. MTX has a favourable efficacy to toxicity
profile over short and intermediate periods compared
with other disease-modifying anti-rheumatic drugs
(DMARDs) [4]. Nevertheless, in recent years there
have been a growing number of communications
about MTX-related pulmonary complications [5, 6].
Among the non-infectious adverse effects, interstitial
pneumonitis, lung fibrosis, accelerated pulmonary
nodulosis and drug-induced asthma have been
reported. Among the pulmonary infections, Pneumo-
cystis carinii pneumonia has been described most
frequently [7]. Lung fibrosis and nodulosis may be
pulmonary manifestations of RA itself [8]. A slowly
progressive restrictive pattern and a deterioration of
gas exchange may develop. Therefore, it may be very
difficult to relate this pathology to MTX treatment or
the underlying disease, or both.
There is some controversy about the usefulness
of pulmonary function testing in patients with RA
treated with low-dose MTX [9-11]. In the present
study, we investigated lung volumes and gas exchange
prospectively in a cohort of patients with RA with
the following aims: (1) to determine the incidence
of pulmonary complications requiring MTX with-
drawal, (2) to assess pulmonary function over time and
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(3) to search for risk factors for a loss of pulmonary
function.
PATIENTS AND METHODS
Patients
Between September 1988 and July 1992, patients
with RA were recruited from the in- and out-patient
Department of Rheumatology, University Hospital,
Berne. All patients fulfilled the modified ARA criteria
[12] and had disease activity sufficient to warrant the
introduction of low-dose MTX. Patients were excluded
from the study according to the following criteria: renal
failure denned by a serum creatinine >1.2 times
the upper limit of the reference range; active liver
disease with laboratory evidence of liver cell necrosis;
patients with a significant history of alcohol
consumption and unwillingness to refrain from regular
alcohol consumption; active bone marrow disease
defined by leucopenia <3OOO/mm3 or thrombopenia
<100 000/m3; patients testing positive for human
immunodeficiency virus (HIV); pregnant women and
patients of child-bearing age not practising effective
contraception. Informed consent was obtained from all
patients at the start of the study.
Methotrexate treatment
Weekly i.m. MTX injections, usually between 10
and 15mg, were started. Every single dose applied
was documented on a patient control sheet and the
cumulative dose calculated. Regular clinical follow-ups
were performed, usually every 3 months or in the case
© 1996 British Society for Rheumatology
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of deterioration. Appropriate safety investigations
included full haematology, liver and renal function
tests, and erythrocyte folate concentrations. Weekly
MTX doses were repeatedly adjusted according to
disease activity, minor side-effects, potential inter-
actions with concomitant drug treatment and renal
function. Reasons for stopping MTX were carefully
documented and classified into the following
categories: pulmonary and non-pulmonary adverse
effects of MTX, disorders associated with an increased
risk for the development of MTX adverse effects,
inefficacy of MTX, remission of RA, and disorders
not directly related to RA or MTX. In the case of
incomplete follow-up of pulmonary function testing,
special attention was paid to verification of non-com-
pliance due to different reasons in order not to miss any
adverse effects of MTX. If MTX was stopped for > 1
month for any reason, results obtained after the
interruption were not included in the evaluations.
Non-steroidal anti-inflammatory drugs, low-dose oral
corticosteroids and other drug treatments were
continued as necessary. Folic acid was substituted in
the case of decreased erythrocyte folate level.
Pulmonary function tests
Before the introduction of MTX, and every year
thereafter, an extensive pulmonary assessment was
performed. A history was taken about dyspnoea,
cough, expectoration and smoking. An extensive
physical examination was carried out, looking for signs
of pulmonary and cardiovascular diseases. Detailed
pulmonary function tests comprised forced vital
capacity (FVC), forced expiratory volume in 1 s (FEV,)
before and after inhalation of 0.2 mg salbutamol,
FEV,/FVC, residual volume (RV), total lung capacity
(TLQ and transfer factor using the indicator gas
CO (Tuco). After puncture of the radial artery at
rest and after exercise, if possible despite physical
disability, arterial blood samples were analysed for
partial pressures of oxygen (P^o,) and carbon dioxide
(P«,co,), pH, base excess (BE) and CO haemoglobin
(HbCO). All tests were performed by experienced staff
using the same apparatus. Observed values were
compared with those predicted for patients of similar
age, sex and height as described by the official
statement of the European Respiratory Society [13,14].
Alveolar (A)-arterial (a) Po, gradients, P(A^XOJ,
were calculated according to the alveolar gas
equation P(A-#W>J (mmHg) = [(barometric pressure
(mmHg) - 47) x 0.209] - (1.25 x P^co, (mmHg)) -
P.,o, (mmHg). Values were considered normal if
P(A-.XO, (mmHg) was less than two-fifths of the age
(in years) of the patient. Smokers were defined by a
HbCO 5s 2.0% at rest.
Chest X-rays in two projections were performed by
standard techniques. Data collection was stopped in
June 1994.
Calculations
The mean weekly MTX dose was estimated by
dividing the cumulative dose at the time point of the
last pulmonary function testing by the duration of
treatment. Change in pulmonary function over time
was assessed by calculations of slopes for each
parameter in each individual. In the 22 patients with
two measurements only, the slope of the fitted line
was calculated. In the 57 patients with three or
more values, linear regression analyses were performed.
Each individual graph was carefully studied for
deviation from linearity (sudden change, curvature).
Use of the linear model was judged appropriate for all
parameters. The mean coefficients of variations
calculated and the percentage of patients with
coefficients of variation < 0.2 as an indicator of good
predictive power of the linear regressions were as
follows: FVC 0.04, 100%; FEV, before inhalation
0.04, 100%; FEV, after inhalation 0.05, 98%; Tuco
0.10, 94%; P(A-«),o, at rest 0.25, 46%; P^-xo, after
exercise 0.35, 28%. Therefore, the precision of the
slopes estimated was good for FVC, FEV, before and
after salbutamol, and TL,CO, but poor for P(A-.),o, at rest
and after exercise.
Further statistical analyses included calculations
of mean, standard deviation (S.D.), 5th and 95th
percentiles (5-95 PC), one-group r-test and Spearman's
rank correlation R,. The significance level was set at
P = 0.05.
RESULTS
The 96 patients with RA included in the study had
a mean disease duration of 9.3 yr (s.D. 10.0) and 72
(75%) patients were rheumatoid factor positive. Mean
age was 61 yr (s.D. 13.6), 66 were women, 30 were men;
mean weight was 64 kg (s.D. 11.3), mean height 162 cm
(s.D. 9.2) and mean serum creatinine at entry to the
study 82/imol/l (s.D. 17.3) (reference range 44—115).
Serum creatinine was 95% of the baseline value (s.D.
13.5) at the end of the study. Thirty-one (32%) patients
were smokers.
Lung volumes and gas exchange before treatment
with low-dose MTX are summarized in Table I.
Until the end of the study in July 1994, the mean
duration of MTX treatment was 2.9 yr (5-95 PC
0.4-5.3) and mean weekly MTX dose was 13.0 mg
(5-95 PC 7.6-20.8). The time course of the number of
patients with pulmonary function tests and MTX
withdrawal is shown in Fig. 1. Follow-up was
incomplete in 18 patients (18.8%) due to different
MTX-unrelated causes and MTX was stopped in a
total of 35 patients (36.5%). The reason was remission
of RA in nine patients (9.4%), concomitant disorders
not related to RA or MTX in seven patients (7.3%),
inefficacy of MTX in four patients (4.2%), toxicity of
MTX in 15 patients (15.6%) with adverse effects of
MTX in 10 patients (10.4%) or concomitant disorders
necessitating interruption of MTX treatment in order
to prevent MTX adverse effects in five patients (5.2%):
gastrointestinal intolerance (n = 3), stomatitis (n = 2),
4-fold increase of aminotransferases (n = 1), cutaneous
vasculitis (n = 1), accelerated nodulosis (n = 1), post-
injection pruritus (n = 1), extended infections {n = 3),
infection of a hip prothesis (n = 1) and development of
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TABLE I
Lung volumes and gas exchange in 96 patients with rheumatoid arthritis before and during treatment with low-dose methotrexate. For
abbreviations and calculation of predicted values, see Patients and methods. The significance levels of the mean annual changes during treatment
with MTX were calculated by the one-group /-test
Parameter
FVC
FEVi/FVC before inhalation
FEVi/FVC after inhalation
Tuco
PIA-^OJ at rest
P(A-^.O, after exercise
Unit
ml
% predicted
%
%
ml/min/mmHg
% predicted
mmHg
mmHg
Mean values at baseline
(5th-95th percentile)
3427 (1930-5240)
117(89-162)
70 (47-87)
73 (50-88)
21.4 (12.9-32.0)
88 (61-115)
19.9 (0.6-34.5)
9.7 ( -3 .4 to 29.6)
Mean annual change during
treatment with MTX (per year)
(5th-95th percentile)
- 2 1 ( - 2 9 0 to +316)
+ 0.8 ( -8 .1 to +14.0)
- 0 . 8 ( - 8 . 4 to +3.2)
- 1 . 3 ( -7 .8 to +3.9)
- 0 . 6 ( -4 .0 to +1.9)
- 2 . 1 ( -16 .2 to +11.8)
+ 1.7 ( -5 .2 to +12.2)
+ 1.8 ( -3 .5 to +9.0)
P
n.s.
n.s.
<0.05
< 0.001
<0.01
<0.05
< 0.001
<0.01
respiratory symptoms (n = 2). A 70-yr-old man
developed a probable MTX pneumonitis according to
Searles' or Carson's criteria [15, 16] within a few days
after 6 months of low-dose MTX treatment with a
cumulative dose of 405 mg. A 77-yr-old man showed
progression of a pre-existing rheumatoid lung disease
with progressing restrictive ventilatory defect and
deteriorating gas exchange after 16 months of MTX
treatment with a cumulative dose of 1305 mg. The
relation to MTX treatment is arguable. Therefore, MTX
was stopped in two patients because of respiratory
complaints, resulting in an incidence of 0.72 withdrawals
per 100 patient-years due to pulmonary complications.
Individual annual changes in lung volumes and gas
exchange during MTX treatment are summarized in
Table I. FVC remained stable over time. In contrast,
mean FEVi/FVC decreased little but statistically
significantly before and after inhalation (/ = 2.04,
P<0.05 and / = 3.35, P< 0.001, respectively).
In addition, gas exchange deteriorated with a
significant decrease of mean TUCo (' = 2.58, P < 0.01
for observed values and f=1.88, P < 0.05 for
measured values related to predicted values) and with
significant increases in mean P(A-»,O, at rest and after
exercise (/ = 3.22, P < 0.001 and t = 2.68, P < 0.01,
respectively).
Risk factors for a loss of pulmonary function during
MTX treatment were sought. No effect of gender,
smoking and the presence of rheumatoid factor became
evident. In addition, no correlations were found
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FIG. 1.—life table graph with the number of patients with pulmonary function tests and withdrawal of MTX due to different reasons over time.
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FIG. 2.—Plot of the annual change in FEV./FVC versus FEVi/FVC at baseline after inhalation. Patients with a small number of tests showed
a higher variability of the slopes calculated than patients with 4-7 tests.
between individual annual change in lung volumes or
gas exchange and age, mean weekly MTX dose or FVC
at baseline. In contrast, significant negative correla-
tions were revealed between individual annual change
in FEV,/FVC and FEV,/FVC at baseline before and
after inhalation (both R, = - 0.46, P < 0.001) (Fig. 2).
These findings were upheld for the proportional annual
changes of FEV,/FVC in relation to FEV,/FVC at
baseline {R. = - 0.39, P < 0.0004 and R. = - 0.27,
P = 0.017, respectively). In addition, a negative
correlation was found between individual annual
change in TL,CO and TUCo at baseline (R, = —0.31,
Reasons for deterioration of FVC
Individual change
in FVC (%
Number Age Sex predicted per year)
Individual change
in FEV./FVC
after inhalation
(% per year)
TABLE II
in 10 patients with
Individual change
in Tua> (%
predicted per year)
RA treated with low-dose MTX
Individual change
in P(A-U>I after
exercise
(mmHg per year) Reasons for deterioration
MTX
related
77 - 25.5 (2)
2
3
4
5
6
7
8
9
10
71
63
80
79
76
79
63
71
55
f
f
m
f
f
f
m
m
m
- 1 1 . 8 ( 2 )
- 8.1 (7)
- 8.1 (2)
- 7.7 (2)
- 7.5 (3)
- 7.3 (3)
- 6.4 (3)
- 6.2 (4)
- 6 . 1 (4)
1.0 (2) - 24.7 (2)
5.3(2)
1.6(7)
-11.6(2)
1.1 (2)
3.7 (3)
- 11 (3)
- 0.2 (3)
- 2 . 0 ( 4 )
- 3.9 (4)
NA
NA
- 3.4 (2)
4.5 (2)
- 0.2 (3)
11.8(2)
- 13.5 (3)
- 2.7 (4)
- 1 1 . 9 ( 4 )
NA Progression of interstitial ( - )
pneumopathy
NA Cardiac failure —
-0.1(2) Progression of COPD, -
pulmonary embolism
NA Progression of pleural —
effusions
9.7 (2) Deterioration within normal -
range
NA Deterioration within normal —
range
NA Deterioration of asthma —
bronchi ale
1.9 (2) Progression of Caplan's ( —)
syndrome^ecurrent pleural
effusions
NA Progression of COPD -
NA Thoracic surgery, deteriora- —
tion of asthma bronchiale
NA — not available (number of pulmonary function tests).
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P = 0.028), which became insignificant after analysing
the proportional annual change in Tuco in relation to
TUco at baseline (R. = — 0.22, n.s.). Finally, a negative
correlation was found between the individual annual
change in FVC and P(A-.WJ, after exercise at baseline
OR. = - 0.35, P = 0.029).
Table II summarizes information about 10 patients
with a pronounced loss of FVC, defined by negative
annual changes of FVC below the 16th percentile of the
whole cohort. All clinical, functional and radiological
findings were reviewed and reasons for deterioration
postulated. In addition, 10 patients had a deterioration
of gas exchange with either a decrease in TL,CO below
the 16th percentile (n = 7) or an increase in P(A-«),O,
after exercise above the 84th percentile (n = 3).
Reasons were postulated to be deterioration of asthma
bronchiale (« = 1), progression of chronic obstructive
pulmonary disease (COPD) (n = 1) or not evident
(« = 8).
DISCUSSION
The present study assessed pulmonary function
prospectively in a cohort of 96 patients with RA
selected without regard to pulmonary disorders. The
withdrawal rate due to pulmonary complications was
low. The prevalence of MTX pneumonitis was 1%
after a mean treatment period of 2.9 yr. This rate was
at the lower part of the range between 0.3 and 11.6%
reported by several retrospective and prospective
studies [5]. The incidence of acute MTX pneumonitis
was one case per 276 patient-years which was
considerably lower than the rates of one case per 26
and 50 patient-years, respectively, observed by
retrospective studies [16, 17]. None of the patients
developed an opportunistic pulmonary infection.
Microscopic examinations and extensive cultures of
sputum and bronchoalveolar lavage fluid, and serolog-
ical tests for common respiratory viruses, Mycoplasma,
rickettsia and Legionella, were all negative in the
patients experiencing respiratory symptoms. Two
patients showed a worsening of pre-existing interstitial
pulmonary disease. In addition, deterioration of
asthma bronchiale, progression of COPD, pulmonary
embolism, pleural effusions, thoracic surgery and
cardiac failure were regarded as being responsible
for declines in pulmonary function in some patients.
There are little pathognomonic clinical, laboratory
or radiological features which allow differentiation
between MTX-related pulmonary pathology and
underlying diseases. Chronic interstitial pneumonitis
with lymphocytic and plasma cell infiltrates as well as
fibrosis unrelated to drug therapy can be found in lung
biopsies of patients with RA [18]. Exacerbation of this
lingering process by MTX is possible. Nevertheless,
prevalence and incidence rates of chronic MTX-related
interstitial pneumonitis will remain arbitrary and are
deliberately not calculated in the present study.
Values of FVC were high at baseline and remained
stable throughout the observation period in the
majority of our patients. These findings are in
agreement with longitudinal assessments of patients
with RA treated with low-dose MTX over 24 and 42
weeks, respectively [10, 11]. Similarly, no significant
loss of FVC was found in patients with RA treated with
D-penicillamine and various other DMARDs for at
least 6 months [19]. In contrast, follow-up studies
reported a significant decrease in FVC in patients with
RA treated with aurothiomalate for 2 yr and different
DMARDs for 8 yr, respectively [20, 21].
Our data revealed a significant annual decrease in
FEV,/FVC both before and after inhalation, indicating
some increasing airflow obstruction. Patients already
with an airflow obstruction at baseline were not at an
increased risk of deterioration during MTX treatment.
These findings contrast with other longitudinal
evaluations, which found no significant changes of
FEVi over 24 and 42 weeks of MTX treatment [10, 11].
Nevertheless, a case report gave evidence for the
induction of clinical and laboratory features of asthma
and an increase in airway responsiveness to metha-
choline chronologically related to the weekly intake of
7.5 mg MTX [22]. Another case report described a
patient with a history of well-controlled asthma, whose
respiratory symptoms reappeared while receiving MTX
therapy [23]. However, in unselected patients with
RA treated with different DMARDs, the frequency
of airflow obstruction and bronchial reactivity was
significantly increased compared to controls with
minor degenerative joint disorders [24]. Follow-up
assessments of patients treated with D-penicillamine,
aurothiomalate and other DMARDs gave conflicting
results, with only some of them developing obstructive
ventilatory defects [19-21]. MTX has been
recommended as an effective and safe glucocorticoid-
sparing agent in asthma [25, 26]. However, its efficacy
remains controversial [27]. The question emerged
whether MTX treats or induces asthma [28]. In
analogy, the question can be added whether MTX
diminishes airways inflammation associated with
bronchial narrowing and hyper-reactivity in RA or
causes drug-induced airflow obstruction.
Our results showed a deterioration of gas exchange
over time reflected by a significant annual decrease in
TL,CO and significant annual increases in PCA-IXO, at rest
and after exercise. The latter have to be interpreted
with caution as values in individual patients revealed
considerable variations over time, resulting in high
coefficients of variation of the annual changes
calculated. In addition, only half of the patients had
measurements after exercise because of physical
disability. Nevertheless, our findings differ from
observations in smaller numbers of patients treated
with MTX over shorter periods [10, 11]. On the other
hand, follow-up assessments of patients treated with
D-penicillamine, aurothiomalate and various other
DMARDs gave conflicting outcomes with decreases
[19, 20] and increases [21] of TL,CO- Again, our patients
with a low TL,CO or high P(A-«),O, at baseline did not have
an increased risk for a further deterioration during
MTX therapy.
In summary, the present study illustrates the
favourable safety of low-dose MTX treatment in RA.
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Withdrawal of MTX due to pulmonary side-effects was
rare and represents a justified risk in view of the
improvement of the disease in the majority of patients.
FVC remained stable once allowance had been made
for the physiological effects of ageing. Decreases in
expiratory airflow and gas exchange were measured.
Although these changes were statistically significant,
the amounts were moderate and clinically insignificant
in view of the reliability of the methods applied [13, 14]
and reflect, at least in part, the normal process of
ageing. Considerable interindividual differences were
observed. However, we were unable to detect risk
factors such as mean weekly MTX dose, age, gender,
smoking, the presence of rheumatoid factor and
pulmonary function tests at baseline. In our patients,
disease activity is changing all the time. Because of this
no associations with disease activity were explored.
This is in contrast to an attempt in a cross-sectional
study in juvenile chronic arthritis [29]. Our study also
demonstrates the difficulty and occasional impossibility
of categorizing pulmonary abnormalities into pul-
monary involvement of RA, concurrent unrelated
pulmonary diseases and manifestations of adverse drug
reactions. It rather emphasizes the interrelated nature
of the clinical presentation of each patient who deserves
individual evaluation. Our practical experience during
this study showed that pulmonary function tests at
baseline helped in discerning the different causes of
respiratory symptoms developed during MTX treat-
ment. However, in view of the data presented, costly
routine measurements of lung volumes and gas
exchange no longer seem justified in all patients.
Pulmonary function tests before and during MTX
treatment are recommended only in the case of a
history of lung disease, the presence of respiratory
symptoms, abnormal clinical signs or alterations on
chest X-rays.
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